Engineering Safer Antithrombotic Strategies for Secondary Stroke Prevention
August 29, 2026
Munich
Translating Evidence Into Practice: Myosin Inhibition Across the HCM Spectrum
August 30, 2026
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
Muthiah Vaduganathan, MD, MPH
Koichiro Kinugawa, MD
Michael Böhm, MD
Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
Extra Innings – Sustaining Victory Beyond the First Game
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
FXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC
Ashkan Shoamanesh, MD
Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Maria Pabon, MD
Robert J. Mentz, MD, FHFSA, FACC
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
Javed Butler, MD
Prof. Dr. Johann Bauersachs
Carolyn S. P. Lam, MBBS, PhD
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Richard E. Pratley, MD
David Cherney, MD, PhD
prof. Hiddo Heerspink
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Erin Bohula, MD, DPhil
Lawrence Leiter
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Prof. Dr. Francesc Xavier Cos Claramunt
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.